Proteome Regulatory News (PRM)

5 Sep 2006 09:54

PROTEOME SCIENCES plc PRESS RELEASE For immediate release 5th September, 2006 PROTEOME SCIENCES APPOINTS DR. PETER SCHULZ-KNAPPE AS RESEARCH AND DEVELOPMENT DIRECTOR The Board of Proteome Sciences plc ("Proteome Sciences" or "the Company") ispleased to announce the appointment to the Board of the Company of Dr. PeterSchulz-Knappe as Research and Development Director.Awards of nil cost options under the Company's Long Term Incentive Plan weregranted to Dr. Schulz-Knappe on 1st August, 2006 when he joined the Group andwere calculated at a price of 36 pence per share as follows:Number Face Value of the Share Award319,444 ‚£115,000The information required by rule 17 and Schedule 2 paragraph (g) of the AIMRules in relation to the appointment of Dr. Peter Schulz-Knappe is set outbelow:Name: Peter Schulz-Knappe Age: 44 Previous Names: N/A Directorships and Partnerships held in the BioVisioN AG last 5 years indicating those which are BioVisioN KG current: Digilab BioVisioN GmbH PSK Vermƒ¶gensverwaltende GmbH KBD Beteiligungs GmbH KBD GmbH & Co. KG Unspent Convictions in relation to indictable offences: None Details of any bankruptcies or individual voluntary arrangements: None Details of any insolvency in respect BioVisioN AG - went into receivership of any Company that the Director on 21 Oct 2005 was a director of: Details of any insolvency of any partnership of which the Director was a partner of: None Details of any public criticisms etc: None Notes to editors:Proteome Sciences plcProteome Sciences, a global leader in applied proteomics, uses high sensitivityproprietary technologies to detect differentially expressed proteins indiseases. The protein biomarkers discovered in body fluids or tissues arevalidated, developed and commercialised as diagnostic, prognostic ortherapeutic products through strategic alliances and out-licensing.Through its unique ProteoSHOP‚® toolbox, Proteome Sciences provides highsensitivity/high throughput proteomics solutions, including traditional twodimensional gel-based electrophoresis (2DE) and proprietary gel-free proteinsequence tag technologies (PST‚®, qPST¢â€ž¢& TMT‚®), to major pharma, biotechnologyand diagnostic companies, to discover and exploit protein biomarkers.Sensitizer‚® chemical mass tags have been developed separately as a series ofstand-alone reagents.For further information please visit www.proteomics.comEnquiries:Proteome Sciences plcChristopher Pearce, Chief Executive OfficerEmail: christopher.pearce@proteomics.comJames Malthouse, Finance DirectorEmail: james.malthouse@proteomics.comTel: +44 (0)1932 865065Public Relations for Proteome SciencesIKON AssociatesAdrian ShawTel: +44 (0)1483 535102Mobile: +44 (0)797 9900733Email: adrian@ikonassociates.comENDPROTEOME SCIENCES PLC